Absci Reports Positive Interim Phase 1 Data for ABS-201 in Hair Loss Trial, Advances to MAD Phase
Summary
Absci Corp announced positive interim Phase 1 data for its lead drug candidate, ABS-201, showing favorable safety and pharmacokinetics, leading to the advancement of the trial into the multiple ascending dose phase.
Key Events
-
Positive Interim Phase 1 Data for ABS-201
Absci reported favorable interim Phase 1 data for ABS-201, its novel anti-prolactin receptor antibody for androgenetic alopecia.
-
Favorable Safety and PK Profile
The study drug was well tolerated with no serious adverse events, and pharmacokinetic data supports a potential dosing interval of two or three injections over six months.
-
Advancement to Multiple Ascending Dose (MAD) Phase
The trial has progressed to the multiple ascending dose (MAD) portion in participants with androgenetic alopecia, indicating confidence in the drug's profile.
-
Future Proof-of-Concept Data Expected
Interim proof-of-concept data is anticipated in the second half of 2026, with full data expected in early 2027.
Analysis
This 8-K announces positive interim Phase 1 data for Absci's lead therapeutic candidate, ABS-201, targeting androgenetic alopecia. The favorable safety and pharmacokinetic profile, including a long half-life supporting convenient dosing, is a significant de-risking event for a clinical-stage biopharmaceutical company. The progression to the multiple ascending dose (MAD) portion of the trial is a crucial step forward, providing validation for its generative AI drug discovery platform, especially following recent reports of declining revenue and widened net losses.
At the time of this filing, ABSI was trading at $7.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.24 to $8.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.